ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 281 filers reported holding ROYALTY PHARMA PLC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,035,556 | +0.9% | 185,540 | +14.2% | 0.01% | 0.0% |
| Q2 2023 | $4,993,098 | +16.2% | 162,430 | +36.1% | 0.01% | 0.0% |
| Q1 2023 | $4,298,811 | +1.8% | 119,312 | +11.3% | 0.01% | -16.7% |
| Q4 2022 | $4,223,050 | +6.8% | 107,184 | +8.9% | 0.01% | -7.7% |
| Q3 2022 | $3,953,000 | +4.1% | 98,384 | +9.0% | 0.01% | -23.5% |
| Q2 2022 | $3,796,000 | +19.4% | 90,284 | +10.7% | 0.02% | +30.8% |
| Q1 2022 | $3,179,000 | -2.6% | 81,584 | -1.7% | 0.01% | 0.0% |
| Q4 2021 | $3,263,000 | +104.1% | 83,036 | +87.7% | 0.01% | +62.5% |
| Q3 2021 | $1,599,000 | +7.4% | 44,236 | +21.7% | 0.01% | 0.0% |
| Q2 2021 | $1,489,000 | -6.8% | 36,336 | -0.8% | 0.01% | -20.0% |
| Q1 2021 | $1,597,000 | +47.3% | 36,613 | +69.0% | 0.01% | +25.0% |
| Q4 2020 | $1,084,000 | – | 21,664 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |